|
業務類別
|
-- |
|
業務概覽
|
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includesoff-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue. |
| 公司地址
| Lichtstrasse 35, Basel, CHE, 4056 |
| 電話號碼
| +41 613241111 |
| 傳真號碼
| +41 613247826 |
| 公司網頁
| https://www.novartis.com |
| 員工數量
| 75267 |
| Dr. Vasant Narasimhan |
Chief Executive Officer |
瑞郎 1.90M |
04/02/2026 |
| Dr. Fiona H. Marshall, PhD |
President, Biomedical Research |
-- |
04/02/2026 |
| Mr. Carulla Victor Bulto |
President, US |
瑞郎 855.60K |
04/02/2026 |
| Dr. Patrick Horber, M.D. |
President, International |
瑞郎 1.03M |
04/02/2026 |
| Dr. Aharon Gal, PhD |
Chief Strategy and Growth Officer |
-- |
04/02/2026 |
| Mr. Robert Kowalski |
Chief People and Organization Officer |
-- |
04/02/2026 |
| Dr. Steffen Lang, PhD |
President, Operations |
-- |
04/02/2026 |
| Ms. Karen L. Hale |
Chief Legal and Compliance Officer |
-- |
04/02/2026 |
| Dr. Shreeram Aradhye, M.D. |
President, Development and Chief Medical Officer |
-- |
04/02/2026 |
| Mr. Harry Kirsch |
Chief Financial Officer |
瑞郎 1.15M |
04/02/2026 |
|
|
| Dr. Giovanni Caforio, M.D. |
Chairman of the Board |
04/02/2026 |
| Ms. Ana de Pro Gonzalo |
Independent Director |
04/02/2026 |
| Mr. Ton Buechner |
Independent Director |
04/02/2026 |
| Ms. Bridgette P. Heller |
Independent Director |
04/02/2026 |
| Mr. John Douglas Young |
Independent Director |
04/02/2026 |
| Mr. Daniel Hochstrasser |
Independent Director |
04/02/2026 |
| Ms. Elizabeth McNally, M.D.,PhD |
Director |
04/02/2026 |
| Mr. Frans Van Van Houten, M.Sc. |
Independent Director |
04/02/2026 |
| Mr. Simon E Moroney, D.Phil. |
Vice Chairman of the Board |
04/02/2026 |
| Dr. Nancy C. Andrews, M.D.,PhD |
Independent Director |
04/02/2026 |
| Ms. Elizabeth Doherty |
Independent Director |
04/02/2026 |
| Mr. Patrice Bula |
Lead Independent Director |
04/02/2026 |
|
|
|
|
